Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Ocular Therapeutix (NASDAQ:OCUL) has scheduled its third quarter 2024 financial results conference call and webcast for Thursday, November 14, 2024, at 8:00 AM ET. The company will discuss business progress and financial results for the quarter ended September 30, 2024. The event will be accessible via phone and webcast, with U.S. participants dialing 1-877-407-9039 and international participants using 1-201-689-8470. A replay will be available on the company's website for at least 30 days.
Ocular Therapeutix (NASDAQ:OCUL) ha programmato la sua conferenza sui risultati finanziari del terzo trimestre 2024 per giovedì 14 novembre 2024, alle 8:00 AM ET. L'azienda discuterà i progressi aziendali e i risultati finanziari per il trimestre conclusosi il 30 settembre 2024. L'evento sarà accessibile tramite telefono e webcast, con i partecipanti americani che possono chiamare il numero 1-877-407-9039 e i partecipanti internazionali che possono utilizzare il numero 1-201-689-8470. Una registrazione sarà disponibile sul sito web dell'azienda per almeno 30 giorni.
Ocular Therapeutix (NASDAQ:OCUL) ha programado su llamada de conferencia sobre los resultados financieros del tercer trimestre de 2024 para el jueves 14 de noviembre de 2024, a las 8:00 AM ET. La compañía discutirá el progreso del negocio y los resultados financieros para el trimestre que finalizó el 30 de septiembre de 2024. El evento será accesible por teléfono y webcast, con participantes de EE. UU. llamando al 1-877-407-9039 y participantes internacionales utilizando el 1-201-689-8470. Una grabación estará disponible en el sitio web de la compañía durante al menos 30 días.
Ocular Therapeutix (NASDAQ:OCUL)는 2024년 3분기 재무 실적 컨퍼런스 콜 및 웹캐스트를 2024년 11월 14일 목요일 오전 8:00 ET에 개최할 예정입니다. 회사는 2024년 9월 30일로 종료된 분기의 비즈니스 진행 상황 및 재무 결과에 대해 논의할 것입니다. 이 이벤트는 전화 및 웹캐스트를 통해 접근할 수 있으며, 미국 참가자는 1-877-407-9039로, 국제 참가자는 1-201-689-8470를 사용할 수 있습니다. 재생은 회사 웹사이트에서 최소 30일 동안 이용 가능합니다.
Ocular Therapeutix (NASDAQ:OCUL) a prévu sa conférence téléphonique sur les résultats financiers du troisième trimestre 2024 pour jeudi 14 novembre 2024, à 8h00 ET. L'entreprise discutera des progrès réalisés et des résultats financiers pour le trimestre clos le 30 septembre 2024. L'événement sera accessible par téléphone et par webcast, avec des participants américains composant le 1-877-407-9039 et des participants internationaux utilisant le 1-201-689-8470. Un enregistrement sera disponible sur le site web de l'entreprise pendant au moins 30 jours.
Ocular Therapeutix (NASDAQ:OCUL) hat eine Telefonkonferenz zu den finanziellen Ergebnissen des dritten Quartals 2024 für Donnerstag, den 14. November 2024, um 8:00 Uhr ET angesetzt. Das Unternehmen wird über den Fortschritt im Geschäft und die finanziellen Ergebnisse für das am 30. September 2024 endende Quartal sprechen. Die Veranstaltung ist telefonisch und über das Web verfügbar, wobei US-Teilnehmer die Nummer 1-877-407-9039 und internationale Teilnehmer die Nummer 1-201-689-8470 wählen können. Eine Wiederholung wird auf der Unternehmenswebsite für mindestens 30 Tage verfügbar sein.
- None.
- None.
Conference call and webcast to begin at 8:00 AM ET
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
Conference Call and Webcast Information:
Date: Thursday, November 14, 2024, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (877) 407-9039
Participant Dial-in (International): 1 (201) 689-8470
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When will Ocular Therapeutix (OCUL) report Q3 2024 earnings?
How can investors access Ocular Therapeutix's Q3 2024 earnings call?
How long will Ocular Therapeutix's Q3 2024 earnings webcast be available?
